Abstract
For more than four decades there has been a search for selective inhibitors of GABA transporters. This has led to potent and selective inhibitors of the cloned GABA transporter subtype GAT1, which is responsible for a majority of neuronal GABA transport. The only clinically approved compound with this mechanism of action is Tiagabine. Other GABA transporter subtypes have not been targeted with comparable selectivity and potency. We here review a comprehensive series of competitive inhibitors that provide information about the GABA recognition site and summarise the structure-activity relations in a ligand-based pharmacophore model that suggests how future compounds could be designed. Finally, some of the recent results on subtype-characterised competitive inhibitors and recent lipophilic aromatic GABA uptake inhibitors are reviewed.
Keywords: Acyclic GABA Analogues, THPO, Nipecotic Acid, Aminocyclohexanecarboxylic Acid (ACHC), GABA uptake assay
Current Topics in Medicinal Chemistry
Title: Structure-Activity Relationships of Selective GABA Uptake Inhibitors
Volume: 6 Issue: 17
Author(s): Signe Hog, Jeremy R. Greenwood, Karsten B. Madsen, Orla M. Larsson, Bente Frolund, Arne Schousboe, Povl Krogsgaard-Larsen and Rasmus P. Clausen
Affiliation:
Keywords: Acyclic GABA Analogues, THPO, Nipecotic Acid, Aminocyclohexanecarboxylic Acid (ACHC), GABA uptake assay
Abstract: For more than four decades there has been a search for selective inhibitors of GABA transporters. This has led to potent and selective inhibitors of the cloned GABA transporter subtype GAT1, which is responsible for a majority of neuronal GABA transport. The only clinically approved compound with this mechanism of action is Tiagabine. Other GABA transporter subtypes have not been targeted with comparable selectivity and potency. We here review a comprehensive series of competitive inhibitors that provide information about the GABA recognition site and summarise the structure-activity relations in a ligand-based pharmacophore model that suggests how future compounds could be designed. Finally, some of the recent results on subtype-characterised competitive inhibitors and recent lipophilic aromatic GABA uptake inhibitors are reviewed.
Export Options
About this article
Cite this article as:
Hog Signe, Greenwood R. Jeremy, Madsen B. Karsten, Larsson M. Orla, Frolund Bente, Schousboe Arne, Krogsgaard-Larsen Povl and Clausen P. Rasmus, Structure-Activity Relationships of Selective GABA Uptake Inhibitors, Current Topics in Medicinal Chemistry 2006; 6 (17) . https://dx.doi.org/10.2174/156802606778249801
DOI https://dx.doi.org/10.2174/156802606778249801 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Myopathic Involvement and Mitochondrial Pathology in Kennedy Disease and in Other Motor Neuron Diseases
Current Molecular Medicine Trafficking of Neuronal Two Pore Domain Potassium Channels
Current Neuropharmacology Pharmacological Modulation of the State of Awareness in Patients with Disorders of Consciousness: An Overview
Current Pharmaceutical Design Role of Biotransformation in Conceptal Toxicity of Drugs and Other Chemicals
Current Pharmaceutical Design Editorial [Hot Topic: Membrane Channels as Therapeutic Targets (Executive Editor: Jean-Claude Herve)]
Current Pharmaceutical Design 1,2,4-Triazole Derivatives as Potential Scaffold for Anticonvulsant Activity
Central Nervous System Agents in Medicinal Chemistry On the Discovery and Development of CFTR Chloride Channel Activators
Current Pharmaceutical Design Perinatal and Neonatal Outcomes of Lithium-Treated and Untreated Bipolar Women During Pregnancy: A Review of Present Literature
Current Psychopharmacology Biophysical Modeling and Associated Signal Modeling in Functional Magnetic Resonance Imaging
Neuroscience and Biomedical Engineering (Discontinued) Combination Therapy for Multi-Target Manipulation of Secondary Brain Injury Mechanisms
Current Neuropharmacology Commentary: Gut Microbiota and Brain Function: A New Target for Brain Diseases?
CNS & Neurological Disorders - Drug Targets Classical and New Renin-Angiotensin Signalling in Atherosclerosis
Current Signal Transduction Therapy A Novel Efficient Machine Learning Approach for Multiclass Classification of EEG Signal
Recent Patents on Computer Science Medial Temporal Lobe Volumes in Amnestic Mild Cognitive Impairment and Late-life Depression: Research Synthesis
Current Psychiatry Reviews Elderly Patients with Migraine: An Open-Label Study on Prophylaxis Therapy with Levetiracetam
Central Nervous System Agents in Medicinal Chemistry N-Methyl D-Aspartate (NMDA) Receptor Antagonists and Memantine Treatment for Alzheimer’s Disease, Vascular Dementia and Parkinson’s Disease
Current Alzheimer Research Identification of Novel NaV1.7 Antagonists Using High Throughput Screening Platforms
Combinatorial Chemistry & High Throughput Screening Therapeutic Application of Histone Deacetylase Inhibitors for Stroke
Central Nervous System Agents in Medicinal Chemistry Lamotrigine Induced Whole Body Tics: A Case Report and Literature Review
Current Drug Safety Nonconvulsive (Dialeptic) Status Epilepticus in Children
Current Pediatric Reviews